MX2007012353A - Metodos para el tratamiento de alteraciones relacionadas con la ansiedad. - Google Patents

Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.

Info

Publication number
MX2007012353A
MX2007012353A MX2007012353A MX2007012353A MX2007012353A MX 2007012353 A MX2007012353 A MX 2007012353A MX 2007012353 A MX2007012353 A MX 2007012353A MX 2007012353 A MX2007012353 A MX 2007012353A MX 2007012353 A MX2007012353 A MX 2007012353A
Authority
MX
Mexico
Prior art keywords
methods
related disorders
treating anxiety
anxiety related
compositions
Prior art date
Application number
MX2007012353A
Other languages
English (en)
Inventor
Sanjay Sabnani
Donald Wesson
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of MX2007012353A publication Critical patent/MX2007012353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion es concerniente con metodos de y composiciones para el tratamiento y alivio de sintomas y enfermedades asociadas con indicaciones provocadas por un impulso fisiologico para aliviar una sensacion de ansiedad. En un metodo de tratamiento, metodos de y composiciones para modular la expresion de ciertas unidades del receptor GABAA son usados para tratar alteraciones relacionadas con la ansiedad y alteraciones depresivas asociadas con tolerancia fisiologica a neuroesteroides endogenos.
MX2007012353A 2005-04-07 2006-04-07 Metodos para el tratamiento de alteraciones relacionadas con la ansiedad. MX2007012353A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72901305P 2005-10-21 2005-10-21
US72897905P 2005-10-21 2005-10-21
PCT/US2006/013152 WO2006110580A2 (en) 2005-04-07 2006-04-07 Methods for treating anxiety related disorders

Publications (1)

Publication Number Publication Date
MX2007012353A true MX2007012353A (es) 2008-01-16

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007012355A MX2007012355A (es) 2005-04-07 2006-04-07 Metodos para el tratamiento de abuso y dependencia de sustancia.
MX2007012353A MX2007012353A (es) 2005-04-07 2006-04-07 Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2007012355A MX2007012355A (es) 2005-04-07 2006-04-07 Metodos para el tratamiento de abuso y dependencia de sustancia.

Country Status (12)

Country Link
US (3) US20080207601A1 (es)
EP (3) EP1868593A2 (es)
JP (3) JP2008538748A (es)
KR (2) KR20080004580A (es)
AU (3) AU2006235318A1 (es)
BR (2) BRPI0609744A2 (es)
CA (3) CA2604887A1 (es)
CR (2) CR9410A (es)
IL (2) IL186447A0 (es)
MX (2) MX2007012355A (es)
NO (2) NO20075161L (es)
WO (3) WO2006110642A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
CN101969930A (zh) 2007-12-17 2011-02-09 莱博法姆公司 防滥用控制释放制剂
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
US9283212B2 (en) * 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
WO2012006683A1 (en) * 2010-07-16 2012-01-19 Controlled Release Technologies Pty Ltd Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
LT2806877T (lt) 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
JP6715830B2 (ja) * 2014-06-26 2020-07-01 ザ・ジョンズ・ホプキンス・ユニバーシティ 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
MX2019007504A (es) * 2017-01-09 2020-07-29 Asarina Pharma Ab Suspensiones inyectables.
US20200101066A1 (en) * 2017-03-28 2020-04-02 LDN Pharma Limited Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
AU2018333952A1 (en) * 2017-09-18 2020-04-09 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with opioid withdrawal
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
US10966988B2 (en) * 2017-09-20 2021-04-06 Calista Capital, Llc Method for smoking cessation
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
EP3773599A1 (en) * 2018-04-05 2021-02-17 Asarina Pharma ApS Gaba-a antagonists for treating substance withdrawal disorders
KR20210039324A (ko) * 2018-04-06 2021-04-09 오비드 테라퓨틱스 인크. 물질 사용 장애들의 치료에서 가복사돌의 사용
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
CN114555070A (zh) * 2019-08-26 2022-05-27 经期药丸私人有限责任公司 月经周期诱发的症状治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
AU751496B2 (en) * 1997-08-28 2002-08-15 Vela Pharmaceuticals Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
AU7331300A (en) * 1999-08-27 2001-03-26 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
JP2004519461A (ja) 2001-01-17 2004-07-02 ハイチアム，インコーポレイテッド アルコール依存症治療用薬剤の製造時におけるフルマゼニルの使用
BR0207866A (pt) 2001-02-15 2004-03-23 Hythiam Inc Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
AU2004305563C1 (en) * 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
WO2006110642A2 (en) 2006-10-19
MX2007012355A (es) 2008-01-16
EP1901727A2 (en) 2008-03-26
EP1901727A4 (en) 2009-11-11
US8012958B2 (en) 2011-09-06
WO2006110557A3 (en) 2009-04-16
US20080207601A1 (en) 2008-08-28
CA2603533A1 (en) 2006-10-19
JP2008535850A (ja) 2008-09-04
IL186450A0 (en) 2008-01-20
US20080255097A1 (en) 2008-10-16
WO2006110642A3 (en) 2009-04-23
CR9413A (es) 2008-01-21
BRPI0610693A2 (pt) 2016-11-22
US20080280885A1 (en) 2008-11-13
KR20080004581A (ko) 2008-01-09
AU2006235257B2 (en) 2010-11-04
CA2603519A1 (en) 2006-10-19
AU2006235234A1 (en) 2006-10-19
IL186447A0 (en) 2008-08-07
JP2008538748A (ja) 2008-11-06
AU2006235318A1 (en) 2006-10-19
WO2006110580A2 (en) 2006-10-19
WO2006110580A3 (en) 2007-08-16
CA2604887A1 (en) 2006-10-19
AU2006235257A1 (en) 2006-10-19
WO2006110557A2 (en) 2006-10-19
JP2008535852A (ja) 2008-09-04
EP1868593A2 (en) 2007-12-26
BRPI0609744A2 (pt) 2010-04-27
NO20075161L (no) 2008-01-07
EP1868432A2 (en) 2007-12-26
KR20080004580A (ko) 2008-01-09
CR9410A (es) 2008-02-21
EP1868432A4 (en) 2009-11-04
NO20075155L (no) 2008-01-07

Similar Documents

Publication Publication Date Title
MX2007012353A (es) Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.
HRP20130345T1 (hr) NOVI TERAPIJSKI PRISTUPI ZA LIJEČENJE CMT-a I SRODNIH POREMEĆA
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
EA201070058A1 (ru) Способы лечения опосредованных серотонином заболеваний и расстройств
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
WO2007111993A3 (en) Polyamine analogs as therapeutic agents for skin diseases
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
MX2011006224A (es) Composicion que comprende isoflavonas.
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
BRPI0919944A2 (pt) aparelho e método para tratamento ultrassônico da espinha
NO20083838L (no) Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni

Legal Events

Date Code Title Description
FA Abandonment or withdrawal